Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

Go back to Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Gilead Sciences (NASDAQ: GILD) Delayed: 158.35 +2.31 (1.48%)
Previous Close $156.04    52 Week High $108.63 
Open $157.62    52 Week Low $71.39 
Day High $159.69    P/E 87.49 
Day Low $157.59    EPS $1.81 
Volume 3,618,838